RESPONSE ASSESSMENT AFTER TARE:
mRECIST AND VOLUMETRIC ANALYSIS
Why standard RECIST criteria fail to capture TARE response โ and how mRECIST, LI-RADS Treatment Response, and volumetric CT analysis provide the accurate response assessment that guides ongoing management decisions.
analyticsAt a Glance
- check_circleStandard RECIST measures overall tumour size โ irrelevant after TARE, where tumours may remain large but be pathologically dead
- check_circlemRECIST measures viable tumour (enhancing on arterial phase CT) โ the correct post-TARE response criterion for HCC
- check_circleLI-RADS Treatment Response (LI-RADS TR) provides a structured 5-category radiological response system for HCC
- check_circleCancerFax ensures post-TARE imaging is performed with correct protocol and interpreted using the appropriate criteria
Why Standard RECIST Does Not Work After TARE
Standard RECIST (Response Evaluation Criteria in Solid Tumours) measures the longest diameter of target lesions on CT โ a metric designed for cytotoxic chemotherapy that shrinks tumours. After TARE, tumours may not shrink at all โ or may even appear slightly enlarged due to surrounding oedema and necrotic tissue โ while being pathologically completely dead. Measuring diameter in this context produces misleading 'progressive disease' calls for tumours that have actually been ablated.
โA tumour that looks the same size but has no viable cells is a complete response โ not stable disease. Standard RECIST cannot tell the difference. mRECIST can.โ
The Biology of Radiation Necrosis
Y-90 kills tumour cells by radiation DNA damage โ but does not immediately remove the cellular debris. The necrotic tumour tissue remains in place for months or years, occupying the same volumetric space as the living tumour did. On CT, this necrosis can look almost identical to viable tumour unless enhancement characteristics are examined.
Arterial Enhancement โ The Key to mRECIST
Living HCC cells are hypervascular โ they enhance brightly on the arterial phase of contrast-enhanced CT or MRI. Dead (necrotic) tumour tissue loses its vascular supply and stops enhancing. mRECIST measures the diameter of the enhancing (viable) component โ not the entire tumour including necrosis.
RECIST vs mRECIST โ What Each Criterion Measures
A structured comparison of standard RECIST and modified RECIST (mRECIST) as applied to post-TARE liver tumour response assessment.
| Criterion | Standard RECIST 1.1 | Modified RECIST (mRECIST) |
|---|---|---|
| What is measured | Longest diameter of the entire target lesion | Longest diameter of viable (arterially enhancing) tumour component only |
| Complete Response (CR) | Disappearance of all target lesions | Disappearance of any intratumoral arterial enhancement in all target lesions |
| Partial Response (PR) | โฅ30% decrease in sum of longest diameters | โฅ30% decrease in sum of longest diameters of enhancing tumour |
| Stable Disease (SD) | Neither PR nor PD | Neither mPR nor mPD of viable tumour |
| Progressive Disease (PD) | โฅ20% increase in sum of diameters (or new lesions) | โฅ20% increase in sum of enhancing diameter OR new viable tumour lesions |
| Best suited for | Chemotherapy; cytotoxic agents causing tumour shrinkage | Locoregional therapies (TARE, TACE, ablation) causing tumour necrosis |
| Risk of misclassification after TARE | High โ necrotic tumour misclassified as stable or progressive | Low โ necrosis correctly classified as response |
LI-RADS Treatment Response (LI-RADS TR) โ 5-Category System
LI-RADS TR provides a structured radiological classification for HCC treatment response on CT or MRI โ applicable to any locoregional treatment including TARE. It is increasingly used at specialist centres alongside or instead of mRECIST.
| LI-RADS TR Category | Definition | Imaging Finding | Clinical Implication |
|---|---|---|---|
| TR-NE (Non-evaluable) | Cannot be assessed | Inadequate image quality or no prior baseline | Repeat imaging with optimal protocol |
| TR-1 (No viable tumour) | Complete pathological response likely | No arterial enhancement, no washout in treated area | Best possible response โ surveillance continue |
| TR-2 (Probably no viable tumour) | Likely complete response | Minimal residual enhancement possibly representing treatment effect vs viable tumour | Close surveillance; MRI may clarify |
| TR-3 (Equivocal) | Uncertain โ viable or not | Enhancement characteristics inconclusive | MRI preferred; consider PET or biopsy if critical |
| TR-4 (Probably viable) | Likely residual viable tumour | Focal arterial enhancement with washout in treated area | Consider retreatment (repeat TARE, TACE, ablation) |
| TR-5 (Definitely viable) | Residual viable tumour confirmed | Clear arterial enhancement + washout; new satellite lesions | Retreatment or escalation required |
Post-TARE Imaging Schedule and Protocol
When and how imaging is performed after TARE determines whether response is accurately captured. The timing, modality, and contrast phase selection are all critical.
- 1
Baseline โ Pre-Treatment Imaging
Every patient must have a baseline multiphasic contrast-enhanced CT or MRI performed within 4โ6 weeks before TARE โ measuring enhancing tumour diameter, total tumour burden, and liver volume. Post-treatment response is calculated relative to this baseline.
- 2
Day 30 Imaging โ Early Response Check (Cell Therapy Patients)
For patients undergoing TARE as part of a combined cellular therapy approach (e.g. TARE + CIK or TARE + CAR-T trial), day 30 imaging assesses early response and safety โ though TARE responses typically mature more slowly. For standard TARE, day 30 imaging is used at some centres but is not universally required.',
- 3
First Post-TARE Assessment โ 4โ6 Weeks
The first formal response assessment is typically performed at 4โ6 weeks using multiphasic CT (arterial and portal venous phase) or MRI with hepatobiliary contrast. mRECIST or LI-RADS TR criteria are applied. Tumour necrosis (loss of arterial enhancement) begins to be visible at this time point.
- 4
Consolidated Response Assessment โ 3 Months
The 3-month post-TARE scan is the most important response assessment point โ by this time, radiation necrosis is typically well-established and the enhancement characteristics of treated tumour are clearly interpretable. mRECIST/LI-RADS TR assessment at 3 months drives decisions about retreatment, systemic therapy escalation, or transplant listing.
- 5
Ongoing Surveillance โ Every 3 Months
After the 3-month assessment, surveillance imaging is performed every 3 months for the first 2 years โ looking for recurrence in untreated liver segments, new lesions, or extrahepatic progression. Frequency may be reduced to every 6 months in confirmed long-term responders.',
TARE Response Assessment โ Key Numbers
The most clinically important quantitative reference points for understanding and communicating post-TARE response.
- 3 monthsOptimal timing for first consolidated post-TARE mRECIST assessmentRadiation necrosis is typically fully established by 3 months โ earlier imaging may underestimate response as necrosis continues to evolve.
- ~40โ60%Objective response rate (mRECIST CR+PR) in HCC after high-dose TAREContrast-enhanced CT/MRI using mRECIST โ substantially higher than what standard RECIST would report for the same patient population.
- LI-RADS TR-1Target response category for radiation segmentectomyComplete loss of arterial enhancement (LI-RADS TR-1 or mRECIST CR) is the goal in radiation segmentectomy โ achievable in 25โ35% of treated patients.
Complete the TARE / Y-90 Resource Library
Explore the final guides in the TARE resource library โ from access in China and India to cost comparisons and the complete question guide.
Frequently Asked Questions About Post-TARE Response Assessment
My CT report says 'stable disease' after TARE but the tumour looks darker inside. Does that mean it worked?
Quite possibly. A standard radiologist report using RECIST criteria may read 'stable disease' if the overall tumour dimensions have not changed by the required 30% threshold โ even when the interior of the tumour has lost its arterial enhancement (gone dark on the arterial phase), indicating necrosis. This is a common source of confusion for patients and oncologists. If your post-TARE CT shows reduced or absent arterial enhancement inside the treated tumour, that finding should be interpreted using mRECIST โ which may classify your response as complete or partial. CancerFax can review your post-TARE imaging reports and identify whether the correct response criteria were applied.
How long after TARE should I wait before my first scan?
The most clinically meaningful first response assessment is at 3 months post-TARE โ by which time radiation necrosis is fully established and the enhancing tumour characteristics are clearly interpretable on contrast CT or MRI. Many centres also perform an earlier 4โ6 week scan primarily for safety assessment (liver function, early signs of REILD, treatment-related changes) โ but the 4โ6 week scan should not be used as the primary response assessment point, as it may underestimate the degree of response.
My HCC was treated with TARE and my AFP has actually increased at 4 weeks. Should I be worried?
A transient AFP rise in the first 4โ6 weeks after TARE is not uncommon and does not necessarily indicate treatment failure โ it can reflect tumour cell lysis releasing AFP into the circulation as the radiation-damaged tumour cells die. This pattern mirrors the transient AFP rise sometimes seen after TACE. However, a sustained or progressive AFP rise beyond 8 weeks should be evaluated with repeat imaging to assess for residual viable tumour or new lesion development. CancerFax advises on AFP trajectory interpretation as part of post-TARE follow-up support.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Need Help Interpreting Your Post-TARE Imaging?
CancerFax reviews your post-TARE CT or MRI reports, identifies whether the correct response criteria were applied, and coordinates communication between the Chinese treating centre and your home oncologist to ensure follow-up decisions are based on accurate response assessment.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist and radiologist for interpretation of your imaging.